In addition, various combination therapies have recently been explored in clinical trials, and some combination therapies are being introduced in clinical practice, with particular reference to NSCLC, including combinations of nivolumab and ipilimumab, or platinum-based chemotherapy in association with the anti-PD-1 pembrolizumab, or a combination of platinum-based chemotherapy plus the anti-PD-L1 atezolizumab and the anti-angiogenic bevacizumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.